Novo Nordisk’s decision will force people in developing countries to use outdated glass vials and syringes, warn campaigners
The pharmaceutical company behind injectable weight-loss drugs has been accused of prioritising profits over the health of people in developing countries by halting production of its insulin pens.
People living with type 1 diabetes who are reliant on the human insulin produced by Novo Nordisk, will instead be given glass vials and syringes – which they say are inconvenient and harder to use with the same accuracy.
About Author
More Stories
Nigeria sues crypto giant Binance for $81.5bn in economic losses and back tax
Xi Jinping tells Alibaba’s Jack Ma and Chinese tech chiefs to ‘show their talent’
Apple announces $500bn in US investments over next four years